StockNews.AI
JNJ
StockNews.AI
140 days

Johnson & Johnson Announces Expected Closing Date for Intra-Cellular Acquisition

1. JNJ's acquisition of Intra-Cellular Therapies is approved, boosting 2025 sales growth. 2. Expected 0.8% increase in sales, roughly $0.7 billion additional revenue.

2m saved
Insight
Article

FAQ

Why Bullish?

Acquisitions typically lead to organic growth and enhanced earnings potential. Previous JNJ acquisitions, like Actelion in 2017, resulted in positive stock performance.

How important is it?

The acquisition is a strategic move to enhance JNJ’s revenue base, which could lead to substantial investor returns. The projected sales growth indicates a direct positive impact on JNJ's financial standing.

Why Long Term?

The full benefits of the acquisition will manifest over several quarters, aligning with annual financial impacts. Historical data shows that significant mergers and acquisitions often deliver sustained growth.

Related Companies

INTCPFEMRK
NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) today announced that following the approval of its pending acquisition of Intra-Cellular Therapies, Inc. by Intra-Cellular Therapies' shareholders on March 27, 2025, Johnson & Johnson intends to complete its acquisition of Intra-Cellular Therapies on or around April 2, 2025. The transaction is expected to accelerate 2025 sales growth for Johnson & Johnson by approximately 0.8% with approximately $0.7 billion in incr.

Related News